

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Currently Amended) A method to achieve MHC-class II mediated immunomodulation in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression, the method comprising administering to said ~~mammal~~ human at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to modulate MHC class II expression in said ~~mammal~~ human, wherein the MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression is selected from the group consisting of psoriasis, ~~Type I diabetes~~, multiple sclerosis, and rheumatoid arthritis ~~and atherosclerosis~~.

2. (Currently Amended) A method to achieve MHC-class II mediated immunosuppression in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression, the method comprising administering to said ~~mammal~~ human at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to suppress MHC class II expression in said ~~mammal~~ human, wherein the MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression is selected from the group consisting of psoriasis, ~~Type I diabetes~~, multiple sclerosis, and rheumatoid arthritis ~~and atherosclerosis~~.

3. (Currently Amended) A method to achieve MHC-class II mediated anti-inflammatory effect in a human with an MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression, the method comprising administering to said ~~mammal~~ human at least one statin selected from the group consisting of compactin, atorvastatin, lovastatin, pravastatin, fluvastatin, mevastatin, cerivastatin, and simvastatin, in an amount effective to suppress MHC class II expression in said ~~mammal~~ human,

wherein the MHC Class II-mediated inflammatory or autoimmune disorder characterized by IFN- γ inducible Class II transactivator expression is selected from the group consisting of psoriasis, ~~Type I diabetes~~, multiple sclerosis, and rheumatoid arthritis ~~and atherosclerosis~~.

4. (Cancelled)

 5. (Previously Amended) The method of claims 1, 2 or 3, wherein said human does not suffer from hypercholesterolaemia.

6. (Original) The method of claims 1, 2 or 3, wherein said amount is effective to specifically modulate IFN- γ inducible MHC class II expression.

7. – 14. (Cancelled)

15. (Previously Amended) The method of claims 1, 2 or 3, wherein said statin is administered in the absence of any other immunosuppressive agents.

16. (Previously Amended) The method of claims 1, 2 or 3, wherein said amount is between about 10 to about 80 mg per day.

17. (Previously Amended) The method of claims 1, 2 or 3, wherein said amount is between about 20 to about 40 mg per day.

18. (Previously Amended) The method of claims 1, 2 or 3, wherein said administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; or topical, nasal, oral, ocular or optic delivery.

19. (Original) The method of claims 1, 2 or 3, wherein said administration is made daily.

20. (Original) The method of claim 2 or 3, wherein the immunosuppression or anti-inflammatory effect is the result of repression of T lymphocyte activation.

21. - 37. (Cancelled)